Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Endocrine therapy in pancreatic carcinoma
Autore:
Yamashita, J; Abe, M; Ogawa, M;
Indirizzi:
Kumamoto Univ, Sch Med, Dept Surg 2, Kumamoto 860, Japan Kumamoto Univ Kumamoto Japan 860 h Med, Dept Surg 2, Kumamoto 860, Japan
Titolo Testata:
ONCOLOGY
, volume: 55, anno: 1998, supplemento:, 1
pagine: 17 - 21
SICI:
0030-2414(1998)55:<17:ETIPC>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-BREAST-CANCER; PLASMINOGEN-ACTIVATOR PRODUCTION; RANDOMIZED CONTROLLED TRIAL; HORMONE-RELEASING HORMONE; RAT MAMMARY-TUMORS; CELL-LINE MCF-7; MEGESTROL-ACETATE; TISSUE-TYPE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN THERAPY;
Keywords:
endocrine therapy; pancreatic carcinoma; estrogen dependence; tissue plasminogen activator; medroxyprogesterone acetate;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Yamashita, J Kumamoto Univ, Sch Med, Dept Surg 2, Honjo 1-1-1, Kumamoto 860, Japan Kumamoto Univ Honjo 1-1-1 Kumamoto Japan 860 moto 860, Japan
Citazione:
J. Yamashita et al., "Endocrine therapy in pancreatic carcinoma", ONCOL-BASEL, 55, 1998, pp. 17-21

Abstract

There are indications of the possible effects of sex hormones on pancreatic carcinoma. Estrogen receptor (ER) has been demonstrated in pancreatic tumors in experimental animals and in humans and it has been suggested that endocrine manipulation may be effective in the treatment of pancreatic carcinoma. However, it is still controversial whether this lethal cancer can potentially benefit from endocrine therapy. One explanation for the conflictingdata on the benefit of hormonal manipulation in the treatment of pancreatic carcinoma may stem from the fact that there is no adequate marker to assess estrogen dependency of the pancreatic tumors. In this article, we reviewour work on tissue plasminogen activator as a prognostic guide to evaluatethe efficacy of hormonal therapy in human pancreatic carcinoma, and also suggest that a selected subgroup of patients with this lethal cancer may have a potential clinical benefit from endocrine therapy, especially medroxyprogesterone acetate treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 16:16:45